Diagnosis and Management of Bladder Cancer
-
Upload
meducationdotnet -
Category
Documents
-
view
272 -
download
0
Transcript of Diagnosis and Management of Bladder Cancer
![Page 1: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/1.jpg)
Diagnosis and Management of Bladder Cancer
![Page 2: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/2.jpg)
Gold standards in bladder cancer diagnosis
• Cytology
• Cystocopy plus biopsy
![Page 3: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/3.jpg)
staging classification (UICC 1997) - primary tumour
superficial muscle-invasive
(papillary) (solid)
urothelium
lamina propria
superficial muscle
deep muscle
pTapT1
CIS
pT2apT2b
pT3
perivesical
periureteral
perirenal
fat
Diagnosis and Management in Urology 6th September 2010
![Page 4: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/4.jpg)
Management of Bladder TCC - Superficial Disease -
risk of progression treatment
low ( 2 - 11%) TUR-BT -unifocal, pTa G1/2 +/- intravesical chemotherapy
intermediate ( 29 - 39%) TUR-BT + intravesical
-multifocal pTa, pT1 G1/2, chemo- / immunotherapy recurrences
high ( 40 - 83%) TUR-BT + intravesical
-CIS, pTa/1G3 chemo- / immunotherapy radical cystectomy radiation therapy
![Page 5: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/5.jpg)
Tumour
Bladder Wall
Prostate
Cystoscope
Transurethral resection of the bladder TURB
Diagnosis and Management in Urology 6th September 2010
![Page 6: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/6.jpg)
Non- Surgical Management of Bladder Cancer
![Page 7: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/7.jpg)
CASE HISTORY 1
• 51 yo barman
• 1 episode frank haematuria
• No past Hx
• Smoker, 20/d x 30y
![Page 8: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/8.jpg)
CASE HISTORY 1
• Investigations:
– FBC, U+E
– MSU for C+S
– IVU
– Cystoscopy + Biopsy
![Page 9: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/9.jpg)
CASE HISTORY 1
• Bladder lesion seen at cystoscopy
• Biopsy: Grade 3 TCC, pT1
– But no muscle in sample
• Next step?
![Page 10: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/10.jpg)
CASE HISTORY 1
• TURBT
• Tumour resected
– pT2a (at least)
• Staging investigations?
![Page 11: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/11.jpg)
![Page 12: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/12.jpg)
![Page 13: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/13.jpg)
![Page 14: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/14.jpg)
Treatment Options Localised Muscle Invasive Bladder Cancer
• Radical Cystoprostatectomy
+/- Neo adjuvant chemotherapy
• Radical Radiotherapy
+/- Neo adjuvant chemotherapy
![Page 15: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/15.jpg)
Multi-Disciplinary Team Meeting
• Surgeons, Oncologists, Radiologists, Pathologists, Nurses
• Treatment options discussed
![Page 16: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/16.jpg)
Radiotherapy Versus Surgery
FOR
• Organ Preservation
• Sexual Function
• No anaesthetic
• Suitable for less fit patients
Against
• No randomised data
• Less pathological information
![Page 17: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/17.jpg)
CASE HISTORY 1
• Patient opted for radical radiotherapy with neo-adjuvant chemotherapy
![Page 18: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/18.jpg)
Neo-Adjuvant Chemotherapy
Neo-Adjuvant Chemotherapy Definitive Treatment
Surgery/Radiotherapy
Rationale: Down-staging, micro-metastatic disease control, radiosensitising
![Page 19: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/19.jpg)
Why chemotherapy in invasive bladder cancer?
• 5 yr survival only 50%
• Pattern of recurrence usually distant mets rather than local recurrence
• Suggests treatment failure mainly due to presence of occult metastatic disease present at the time of definitive local treatment, with 20-30% of patients failing locally
![Page 20: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/20.jpg)
Chemotherapy
• Cisplatin initially was the most active single agent used
• As single agent, response rates only 10-30%
• Combination chemotherapy centred around Cisplatin was studied in RCT’s in 1990’s & shown to have ↑ response rates & ↑ OS
![Page 21: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/21.jpg)
Combination Chemotherapy
• Methotrexate,Vinblastine,Doxorubicin and Cisplatin (M-VAC) had been the gold standard until recently
• Limited greatly by toxicity-up to 63% of patients may require dose-reduction
• Long term survival benefit is modest-median survival consistently less than 13 months
![Page 22: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/22.jpg)
Gemcitabine-Cisplatin
• Randomized phase III trial comparing standard M-VAC with Gemcitabine/Cisplatin
• Patients were stage T4b or any N/any M TCC bladder with no previous chemotherapy
• 405 pts enrolled
![Page 23: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/23.jpg)
M-VAC Gem/Cis
No. of patients 202 203
Overall RR 46 49
Complete RR 12 12
Median Survival 14.8 13.8
Rx related dths 3% 1%
Neut. Sepsis 12% 1%
G3-4 mucositis 22% 1%
Mucositis/Cycle 3.6 days 0.5 days
![Page 24: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/24.jpg)
Advantages & Disadvantages of Neo-adjuvant Chemotherapy
• Improved drug delivery before possible interference caused by local treatments
• Better tolerability & compliance due to improved PS
• Immediate Rx of micro-mets • Prognostic information by
observing response to chemotherapy
• May allow bladder preservation in complete responders
• Delayed definitive Rx
• Toxicity & possible lowering of PS before local treatment
• Difficult to assess response in primary
• Possibility of inaccurate clinical staging before treatment
• May treat some patients unnecessarily
![Page 25: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/25.jpg)
Bladder Chemotherapy -Common Side-Effects
• Neutropenia
• Anaemia
• Alopecia
• Nausea and Vomiting
• Peripheral nerve damage
• Renal impairment
• Mucositis
![Page 26: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/26.jpg)
Case 1: Patient Management
• Completed 3 cycles of Gemcitabine-Cisplatin Chemotherapy
• Cystoscopy: complete response
• Plan Proceed to Radiotherapy
![Page 27: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/27.jpg)
Radical Radiotherapy
• CT planned volume – bladder empty
![Page 28: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/28.jpg)
Radiotherapy
• Radiotherapy delivered by Linear Accelerators
• Usually one treatment (fraction) per day for 6-8 weeks
![Page 29: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/29.jpg)
Contouring on multiple CT slices – typically 40 slices
![Page 30: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/30.jpg)
![Page 31: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/31.jpg)
![Page 32: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/32.jpg)
Radiotherapy
• Treated supine with 3 field arrangement
– Anterior,R lateral wedged,& L lateral wedged fields
• 64 Gy / 32 F/ 6.5 wks
![Page 33: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/33.jpg)
Radiotherapy
Acute Side Effects • Diarrhoea
• Proctitis- Urgency, PR bleeding, Mucous Discharge
• Dysuria
• Frequency
• Urgency
• Tiredness
![Page 34: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/34.jpg)
Radiotherapy
Late Side Effects • Reduced bladder capacity
• Reduced erectile function
• Rectal bleeding
• Altered bowel habit
• Second cancer risk
![Page 35: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/35.jpg)
CASE 1
• Tolerated treatment well
• Alive and well 18 months later, cystoscopy clear
![Page 36: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/36.jpg)
CASE HISTORY 2
• 45yr old plumber.
• September 2004
• 1 year history of recurrent macroscopic haematuria, unresponsive to antibiotic therapy.
![Page 37: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/37.jpg)
CASE HISTORY 2
• Cystoscopy
– Tumour at the left ureteric orifice.
• Histology
– Grade 3 Transitional cell carcinoma.
– Muscle invasive.
![Page 38: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/38.jpg)
CASE HISTORY 2
• Pre-operative CT
– Tumour at the left side of bladder with left hydronephrosis
– Small pelvic nodes and two small equivocal pulmonary nodules
![Page 39: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/39.jpg)
CASE HISTORY 2
• Cystectomy
– Frozen section of 2 pelvic nodes
• Positive for metastatic TCC
• pT2b N2 …… M1?
• Referred to oncology
![Page 40: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/40.jpg)
CASE HISTORY 2
![Page 41: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/41.jpg)
Symptoms of Lung Metastases
• Symptoms?
![Page 42: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/42.jpg)
Bladder Metastases
• Other sites of metastases:
– Nodes
– Liver
– Brain
– Bone
– Skin
![Page 43: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/43.jpg)
Treatment Options
• Chemotherapy
– Gemcitabine + Cisplatin
• Radiotherapy for pain/bleeding
![Page 44: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/44.jpg)
Gemcitabine Cisplatin
• Cycle 1-3 well tolerated.
– 2 Lung lesions had remained stable but 2 new 3mm lung lesions found.
– No other disease
• Proceed with Cycle 4-6.
– Stable disease
![Page 45: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/45.jpg)
INDEPENDENT PROGNOSTIC FACTORS
• KPS
– >80 MS 18.5
– <80 MS 10.5
• VISCERAL METASTASIS
– YES MS 11.1
– NO MS 22.3
![Page 46: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/46.jpg)
CASE HISTORY 2
• Stopped chemotherapy July 05
– Pursued an active fitness program
• Returned 3mths later – asymptomatic
• Repeat CT requested for Jan 06
– Progression in the lung lesions
![Page 47: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/47.jpg)
Gemcitabine Cisplatin
• Returned February to start chemo
• Cycle 1-3 (7-9)
– Lesions improved
• Cycle 4-6 (10-12)
– Further improvement
• September 2006 - Stopped chemotherapy
![Page 48: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/48.jpg)
CASE HISTORY 2
• October 2006 - Attended GP
– Numbness in Left Arm for 1½ minute associated with confusion
• Urgent CT brain
![Page 49: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/49.jpg)
CASE HISTORY 2
![Page 50: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/50.jpg)
MRI
![Page 51: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/51.jpg)
WBRT
• Oct 06- 30Gy 10fractions 2weeks
• April 07- RIP
![Page 52: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/52.jpg)
WBRT
– Neurological improvement 50-70%
– Improved survival 3-6mths vs BSC
– Surgery or Stereotactic radiosurgery
• 80% will have CNS relapse.
– WBRT following Sx or SRS
• 20% will have CNS relapse.
Lancet 2004, 363 1665-1672
J Uro 1993, 149, 480-483
![Page 53: Diagnosis and Management of Bladder Cancer](https://reader034.fdocuments.in/reader034/viewer/2022042723/58842bb01a28ab485c8b774d/html5/thumbnails/53.jpg)
CONCLUSION
• Organ preservation is possible with radiotherapy
• Neo-Adjuvant Chemotherapy improves outcome
• Chemotherapy provides excellent palliation in metastatic bladder cancer
• Radiotherapy is useful for palliation of bladder cancer symptoms